Fig. 1
From: CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
CA916798 is upregulated in LUAD and predicts poor survival of patients
A and B) Representative IHC images of CA916798 in matched non-tumor tissue (A) and LUAD tissue (B). Scale bar = 100 μm. Brown color represents CA916798 protein; blue color represents nuclei
C) IHC score of CA916798 expression in matched non-tumor tissue (Normal) and LUAD tissue (Tumor) from Cohort-94. Data are shown as mean ± SD.
D) IHC score of CA916798 expression in different stages of LUAD from Cohort-94. Data are shown as mean ± SD.
E) Kaplan-Meier analysis on overall survival (OS) in LUAD patients with CA916798highvs. CA916798low from Cohort-94
F) mRNA level of CA916798 in matched non-tumor tissue (Normal) and LUAD tissue (Tumor) from TCGA_LUAD dataset. Data are shown as mean ± SD.
G) Kaplan-Meier analysis on 5-year overall survival (OS) in LUAD patients with CA916798highvs. CA916798low from TCGA_LUAD dataset
H) Kaplan-Meier analysis on overall survival (OS) in LUAD patients with CA916798highvs. CA916798low from KM-PLOT-LUAD database
I) Pearson correlation list of methylation levels with CA916798 mRNA expression in TCGA_LUAD mRNA and methylation450K datasets
J) Pearson correlation of CA916798 with cg22306691 from TCGA_LUAD mRNA and methylation450K datasets
K) Kaplan-Meier analysis on 5-year overall survival (OS) in LUAD patients with cg22306691highvs. cg22306691low from TCGA_LUAD methylation450K dataset